Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1972 1
1978 1
1988 1
1989 2
1990 1
1991 1
1992 1
1994 1
1995 1
1997 1
1998 1
1999 1
2003 5
2004 4
2005 2
2008 3
2011 2
2012 1
2013 4
2014 3
2015 1
2016 1
2017 2
2019 1
2020 1
2021 2
2022 1
2023 9

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Triazolopyrimidines identified as reversible myeloperoxidase inhibitors.
Duclos F, Abell LM, Harden DG, Pike K, Nowak K, Locke GA, Duke GJ, Liu X, Fernando G, Shaw SA, Vokits BP, Wurtz NR, Viet A, Valente MN, Stachura S, Sleph P, Khan JA, Gao J, Dongre AR, Zhao L, Wexler RR, Gordon DA, Kick EK. Duclos F, et al. Among authors: harden dg. Medchemcomm. 2017 Oct 26;8(11):2093-2099. doi: 10.1039/c7md00268h. eCollection 2017 Nov 1. Medchemcomm. 2017. PMID: 30108726 Free PMC article.
Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer.
Hanna PE, Strohbehn IA, Moreno D, Harden D, Seethapathy R, Sawtell R, Wang Q, Ouyang T, Katz-Agranov N, Dinulos J, Wander SA, Gupta S, Sise ME. Hanna PE, et al. Among authors: harden d. NPJ Breast Cancer. 2023 Aug 19;9(1):70. doi: 10.1038/s41523-023-00576-5. NPJ Breast Cancer. 2023. PMID: 37598278 Free PMC article.
Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis.
Sise ME, Wang Q, Seethapathy H, Moreno D, Harden D, Smith RN, Rosales IA, Colvin RB, Chute S, Cornell LD, Herrmann SM, Fadden R, Sullivan RJ, Yang NJ, Barmettler S, Wells S, Gupta S, Villani AC, Reynolds KL, Farmer J. Sise ME, et al. Among authors: harden d. J Immunother Cancer. 2023 Jan;11(1):e006222. doi: 10.1136/jitc-2022-006222. J Immunother Cancer. 2023. PMID: 36657813 Free PMC article.
Rapid Compound Integrity Assessment for High-Throughput Screening Hit Triaging.
Shou WZ, Gerritz SW, Harden D, Lawrence RM, Chase P, Chin J, Surti N, Lippy JS, Weller HN, Nielsen J, Weerakoon D. Shou WZ, et al. Among authors: harden d. SLAS Discov. 2021 Feb;26(2):242-247. doi: 10.1177/2472555220919097. Epub 2020 May 13. SLAS Discov. 2021. PMID: 32400264 Free article.
HTS driven by fluorescence lifetime detection of FRET identifies activators and inhibitors of cardiac myosin.
Muretta JM, Rajasekaran D, Blat Y, Little S, Myers M, Nair C, Burdekin B, Yuen SL, Jimenez N, Guhathakurta P, Wilson A, Thompson AR, Surti N, Connors D, Chase P, Harden D, Barbieri CM, Adam L, Thomas DD. Muretta JM, et al. Among authors: harden d. SLAS Discov. 2023 Jul;28(5):223-232. doi: 10.1016/j.slasd.2023.06.001. Epub 2023 Jun 10. SLAS Discov. 2023. PMID: 37307989 Free PMC article.
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy.
Miller MM, Banville J, Friends TJ, Gagnon M, Hangeland JJ, Lavallée JF, Martel A, O'Grady H, Rémillard R, Ruediger E, Tremblay F, Posy SL, Allegretto NJ, Guarino VR, Harden DG, Harper TW, Hartl K, Josephs J, Malmstrom S, Watson C, Yang Y, Zhang G, Wong P, Yang J, Bouvier M, Seiffert DA, Wexler RR, Lawrence RM, Priestley ES, Marinier A. Miller MM, et al. Among authors: harden dg. J Med Chem. 2019 Aug 22;62(16):7400-7416. doi: 10.1021/acs.jmedchem.9b00186. Epub 2019 Aug 5. J Med Chem. 2019. PMID: 31246024
Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma.
Hanna P, Strohbehn I, Moreno D, Harden D, Seethapathy H, Gupta S, Lee M, Ouyang T, Frigault M, Sise ME. Hanna P, et al. Among authors: harden d. Bone Marrow Transplant. 2022 Oct;57(10):1623-1625. doi: 10.1038/s41409-022-01767-7. Epub 2022 Aug 3. Bone Marrow Transplant. 2022. PMID: 35922564 No abstract available.
Discovery of 12 (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders.
Meng W, Brigance R, Mignone J, Negash L, Zhao G, Ahmad S, Wang W, Moore F, Ye XY, Sun JH, Mathur A, Li YX, Azzara A, Ma Z, Chu CH, Cullen MJ, Rooney S, Harvey S, Kopcho L, Abell L, O'Malley K, Keim W, Dierks EA, Chang S, Foster KA, Harden D, Dabros M, Goti V, De Oliveira C, Krishna G, Pelleymounter MA, Whaley J, Robl JA, Cheng D, Devasthale P. Meng W, et al. Among authors: harden d. J Med Chem. 2023 Sep 28;66(18):13135-13147. doi: 10.1021/acs.jmedchem.3c01147. Epub 2023 Sep 19. J Med Chem. 2023. PMID: 37724542
51 results